Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ocumension Enters $77 Million Deal for Stem Cell Therapies from Japan's SanBio

publication date: Apr 1, 2020

Ocumension, a Hong Kong ophthalmology company, partnered with Japan's SanBio to develop novel stem cell therapies for ophthalmic diseases in an agreement worth up to $77 million. The two companies will work together to develop SanBio’s proprietary modified mesenchymal stem cell candidates to treat retinitis pigmentosa, dry age-related macular degeneration and optic neuritis. Ocumension will pay $6 million upfront with the remaining development costs split evenly between the companies. Ocumension, which will also be responsible for $71 million in milestones and China clinical trials, will own China rights to the candidates for ophthalmic indications. More details....

Stock Symbol: (TSE: 4592)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.